Pharmacodynamic Failure — SCE Dermatology MCQ

Correct answer: C — The drug is reaching its target but the disease may be driven by a different inflammatory pathway — switch to a biologic with a DIFFERENT mechanism of action

The correct answer is C: the drug is reaching its target but the disease may be driven by a different inflammatory pathway, so the patient should be switched to a biologic with a DIFFERENT mechanism of action. Adequate trough drug levels with poor clinical response excludes pharmacokinetic failure (low levels, dose-related) and immunogenic failure (low levels plus anti-drug antibodies), leaving pharmacodynamic failure: the drug is present at the site of action but is simply not blocking the pathway that dominates that individual's disease. British Association of Dermatologists guidance on switching biologic therapy in psoriasis recommends reviewing the mechanistic class and moving to an agent that targets a different cytokine axis (for example TNF alpha to IL-17 or IL-23) when response is inadequate despite optimised drug exposure. Simply increasing dose or repeating the same class of drug will not overcome a pathway mismatch, since the target itself, not the drug concentration, is the limiting factor. Why the other options are wrong: E. The test is wrong: therapeutic drug monitoring showing adequate levels is a valid, reproducible result; there is no indication of assay error, and dismissing the result ignores the clinical classification described in the stem. D. Increase the dose: levels are already adequate, so raising the dose adds toxicity risk without addressing the mechanistic mismatch driving non-response. B. Reduce the dose: reducing dose would risk falling below the therapeutic level that is already achieving target engagement, worsening rather than improving response. A. Stop all treatment: abandoning biologic therapy denies the patient other mechanistically distinct options that could achieve disease control; psoriasis remains an active, treatable inflammatory disease. Key point: adequate drug levels with poor response (pharmacodynamic failure) means switch mechanism of action, not dose, because the pathway targeted is not the one driving that patient's disease.

Reference: British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update, British Journal of Dermatology 2020;183(4):628-637 (R21, switching strategies for inadequate response to biologic therapy), https://academic.oup.com/bjd/article/183/4/628/6761584